000 04158nam a22005055i 4500
001 vtls000483844
003 RU-ToGU
005 20210922065713.0
007 cr nn 008mamaa
008 140715s2013 xxu| s |||| 0|eng d
020 _a9781461470700
_9978-1-4614-7070-0
024 7 _a10.1007/978-1-4614-7070-0
_2doi
035 _ato000483844
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
100 1 _aBonavida, Benjamin.
_eeditor.
_9321302
245 1 0 _aMolecular Mechanisms of Tumor Cell Resistance to Chemotherapy
_h[electronic resource] :
_bTargeted Therapies to Reverse Resistance /
_cedited by Benjamin Bonavida.
260 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2013.
300 _aXIII, 260 p. 30 illus., 23 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aResistance to Targeted Anti-Cancer Therapeutics,
_x2196-5501 ;
_v1
505 0 _aPreface -- Multidrug resistance in cancer: a tale of ABC drug transporters -- Multidrug resistance: a role for membrane physics, pH and drug transporters -- Mechanisms and potential therapies for acquired resistance to inhibitors targeting the Raf or MEK kinases in cancer -- Mechanisms of resistance to targeted B-Raf therapies -- Role of β1integrins in the complication and drug resistance against lung cancer: targeting β1integrins to eradicate lung cancer -- Aldo-keto reductases as new therapeutic targets for colon cancer chemoresistance -- Overcoming drug resistance through elevation of ROS in cancer -- Cancer stem cells in resistance to cytotoxic drugs: implications in chemotherapy -- Two birds with a stone: molecular cancer therapy targeting signal transduction and DNA repair pathways -- Collateral sensitivity in drug-resistant tumor cells -- Human cancer resistance to trail-apoptotic pathway-targeted therapies -- The dark side of apoptosis -- Index.
520 _aPatients with various cancers are treated with conventional chemotherapeutic drugs and the majority responds well to such therapies. However, there is a subset of patients who does not respond initially and another subset who no longer responds to further treatments. Clearly, in those two subsets of patients, the cancer cells exhibit mechanisms of resistance. One of the main challenges facing us to date is to develop new therapies to treat patients with the resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance. Such mechanisms have revealed gene products that directly regulate resistance and are targets for therapy. Of interest, several FDA-approved drugs were able to overcome drug resistance and have been successfully used clinically. They have been used as monotherapy or synergized with other therapies for the treatment of resistant tumors. This volume constitutes a total of twelve selective reviews by pioneer scientists in the field of cancer drug resistance. Specific mechanisms in drug resistance are reviewed and novel approaches are being proposed for therapeutic interventions. This volume is of general interest to scientists, clinicians, health care providers, and students.
650 0 _amedicine.
_9566220
650 0 _aOncology.
_9303086
650 0 _aDrug interactions.
_9412159
650 0 _aCytology.
_9269442
650 1 4 _aBiomedicine.
_9566246
650 2 4 _aCancer Research.
_9566267
650 2 4 _aApoptosis.
_9413673
650 2 4 _aCell Biology.
_9302220
650 2 4 _aDrug Resistance.
_9329106
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
830 0 _aResistance to Targeted Anti-Cancer Therapeutics,
_9414060
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-7070-0
912 _aZDB-2-SBL
999 _c356505